N/A
Completed N=35
Comparing Peripherally Inserted Central Catheters to Long Peripheral Catheters in Pediatrics
Vascular Access Device Complications
Source: ClinicalTrials.gov NCT05346406 ↗
Enrolled (actual)
35
Serious AEs
0.0%
Results posted
Jun 2025
Primary outcomePrimary: Percent Eligible Patients That Agreed to Participate — 80 percentage of eligible patients agreed t
Summary
Peripherally Inserted Central Catheters (PICCs) are frequently used in hospitalized children who require prolonged vascular access; however, concerns regarding their inappropriate use and contribution to serious complications such as central line associated blood stream infection (CLABSI) and venous thromboembolism (VTE) have triggered exploration of safer alternatives. Long Peripheral Catheters (LPCs) have been recently adopted by some institutions due to fewer complications as compared to PICCs. The investigators hypothesize that LPCs could be safer alternatives to PICCs for medium-term vascular access (5-14 days) in the appropriate cohort of hospitalized pediatric patients. The primary objective of the proposed clinical effectiveness pilot trial is to test the feasibility of a full-scale effectiveness trial comparing PICCs to LPCs in hospitalized pediatric patients. The investigators aim to identify a population in which LPCs are safe and effective alternatives to PICCs for medium-term, non-central vascular access; data that will inform the design of a full-scale effectiveness study. The investigators plan to engage patients and families as advisors in vascular access device selection by understanding their experience with vascular access device placement and maintenance. Over time, use of LPCs should result in decreased inappropriate PICC utilization with a concomitant decrease in serious complications such as CLABSI and VTE.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Eligible Patients That Agreed to Participate |
80 | — |
| PRIMARY Average Dwell-time |
11.0; 4.7; 8.5; 8.0 | — |
| SECONDARY Number of Participants Who Completed Therapy With Initial VAD |
4; 1; 6; 15 | — |
| SECONDARY Number of Participants With at Least One Complications |
2; 3; 3; 8 | — |
| SECONDARY Number of Participants That Received Sedation for VAD Placement |
4; 3; 5; 18 | — |
| SECONDARY Number of Participants With VAD Successfully Used for Blood Draws |
4; 2; 5; 10 | — |
| SECONDARY Number of Participants Requiring Additional VADs to Complete Therapy |
0; 3; 1; 4 | — |
Eligibility Criteria
Inclusion Criteria
- patients age 2 to 17 years admitted to Children's Wisconsin and requesting placement of a PICC for:
- anticipated length of intravenous treatment of 5-14 days AND
- peripherally compatible infusate AND
- VAD not needed at discharge
Exclusion Criteria
- non-English-speaking family
- active bacteremia or VTE at site where device would be placed
- urgent need of vascular access (within 4 hours)
Data sourced from ClinicalTrials.gov (NCT05346406). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.